Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

This study is testing a combination of two drugs — atezolizumab (an immunotherapy) and pirfenidone (an anti-fibrosis drug) — in patients with advanced non-small cell lung cancer (NSCLC) who have already received prior treatment including immunotherapy. The combination may help overcome resistance to immunotherapy. **You may be eligible if:** - You are 18 or older with confirmed non-small cell lung cancer - Your cancer does not have actionable mutations (like EGFR, ALK, or ROS-1) - You have already been treated with a PD-1 or PD-L1 immunotherapy (alone or with chemotherapy) and no more than 2 prior regimens for advanced disease - You have at least one measurable tumor - You are in reasonably good health (ECOG performance status 0-2) - You are able to swallow oral medications **You may NOT be eligible if:** - Your tumor has an actionable mutation that has targeted treatments available - You have active autoimmune disease requiring treatment - You have had more than 2 prior systemic therapy regimens - You have severe liver, kidney, or heart problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.